The emergence of KRAS inhibitors is reshaping the therapeutic landscape of pancreatic ductal adenocarcinoma (PDAC). Yet responses are seldom durable, and relapse is inevitable, highlighting the ongoing need for aggressive therapeutic strategies. PDAC also remains unresponsive to adoptive T cell therapies (ACT), highl...
D. Evans, Megan M. Wyatt, Anna C. Cole et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains refractory to immunotherapies, including adoptive T cell therapy, necessitating evaluation of alternative T cell engineering platforms in immunosuppressive solid tumors. Human CD4+ T cells co-secreting IFN-γ and IL-17A (Th1/17 hybrids) have demonstrated enhanced ant...
Delaney K. Geitgey, Megan M. Wyatt, Maggie J. Phillips et al.· Cancer Research· 0 citations
While the two transcriptional subtypes (basal-like and classical) of pancreatic ductal adenocarcinoma (PDAC) offer an opportunity for precision medicine, current subtype-specific therapy options are limited to existing frontline therapies with poor outcomes. To determine whether there are epigenetically-driven di...
Erin E. Grundy, Margaret A. Hall, Y. Yoo et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) has traditionally been classified into two overarching transcriptomic subtypes—classical and basal—which have been associated with distinct clinical behaviors and therapeutic responses. We recently identified a previously unrecognized transcriptomic axis governing metastati...
Raymond E. Preston, Hong-Yun Huang, Margaret A. Hall et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
